​

Recursion Pharmaceuticals (RXRX) Revenue & Revenue Breakdown

OverviewForecastOwnershipFinancialsChartTranscripts

Recursion Pharmaceuticals Revenue Highlights

Latest Revenue (Y)

$58.84M

Latest Revenue (Q)

$14.42M

Main Segment (Y)

License and Service

Recursion Pharmaceuticals Revenue by Period

Recursion Pharmaceuticals Revenue by Year

DateRevenueChange
2024-12-31$58.84M32.00%
2023-12-31$44.58M12.33%
2022-12-31$39.68M296.81%
2021-12-31$10.00M193.00%
2020-12-31$3.41M99.47%
2019-12-31$1.71M-

Recursion Pharmaceuticals generated $58.84M in revenue during NA 2024, up 32.00% compared to the previous quarter, and up 3438.87% compared to the same period a year ago.

Recursion Pharmaceuticals Revenue by Quarter

DateRevenueChange
2024-06-30$14.42M4.52%
2024-03-31$13.79M26.66%
2023-12-31$10.89M7.81%
2023-09-30$10.10M-8.30%
2023-06-30$11.02M-9.21%
2023-03-31$12.13M-11.28%
2022-12-31$13.68M4.77%
2022-09-30$13.05M70.56%
2022-06-30$7.65M44.42%
2022-03-31$5.30M111.96%
2021-12-31$2.50M-
2021-09-30$2.50M-
2021-06-30$2.50M-
2021-03-31$2.50M-2.00%
2020-12-31$2.55M195.94%
2020-09-30$862.00K363.44%
2020-06-30$186.00K210.00%
2020-03-31$60.00K-

Recursion Pharmaceuticals generated $14.42M in revenue during Q2 2024, up 4.52% compared to the previous quarter, and up 118.81% compared to the same period a year ago.

Recursion Pharmaceuticals Revenue Breakdown

Recursion Pharmaceuticals Revenue Breakdown by Product

Annual Revenue by Product

Product/ServiceDec 24Dec 23Dec 22Dec 21
License and Service$58.49M$43.88M$39.68M$10.00M
Grant$351.00K$699.00K$162.00K$178.00K

Recursion Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 24: License and Service (99.40%), and Grant (0.60%).

Quarterly Revenue by Product

Product/ServiceDec 24Sep 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21
License and Service$18.91M$26.08M$13.49M$10.62M$10.10M$11.02M$12.13M$13.68M$13.05M$7.65M$5.30M$2.50M$2.50M$2.50M$2.50M
Grant$48.00K$303.00K$267.00K$431.00K$1.00K--$107.00K$21.00K$34.00K$33.00K$34.00K$49.00K$62.00K-

Recursion Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Dec 24: License and Service (99.75%), and Grant (0.25%).

Recursion Pharmaceuticals Peer Comparison by Revenue

TickerCompanyLast Year RevenueLast Quarter Revenue
DAWNDay One Biopharmaceuticals$131.16M$20.07M
RXRXRecursion Pharmaceuticals$58.84M$14.42M
RLAYRelay Therapeutics$10.01M-
AFMDAffimed$8.28M$155.00K
ABSIAbsci$4.53M$898.00K
XFORX4 Pharmaceuticals$2.56M$560.00K
OCEAOcean Biomedical--
IMMXImmix Biopharma--
CNSPCNS Pharmaceuticals--
SANASana Bio--
HEPAHepion Pharmaceuticals--
ABOSAcumen Pharmaceuticals--
INZYInozyme Pharma--
ENVBEnveric Biosciences--

RXRX Revenue FAQ

What is Recursion Pharmaceuticals’s yearly revenue?

Recursion Pharmaceuticals's yearly revenue for 2024 was $58.84M, representing an increase of 32.00% compared to 2023. The company's yearly revenue for 2023 was $44.58M, representing an increase of 12.33% compared to 2022. RXRX's yearly revenue for 2022 was $39.68M, representing an increase of 296.81% compared to 2021.

What is Recursion Pharmaceuticals’s quarterly revenue?

Recursion Pharmaceuticals's quarterly revenue for Q2 2024 was $14.42M, a 4.52% increase from the previous quarter (Q1 2024), and a 30.87% increase year-over-year (Q2 2023). The company's quarterly revenue for Q1 2024 was $13.79M, a 26.66% increase from the previous quarter (Q4 2023), and a 13.68% increase year-over-year (Q1 2023). RXRX's quarterly revenue for Q4 2023 was $10.89M, a 7.81% increase from the previous quarter (Q3 2023), and a -20.36% decrease year-over-year (Q4 2022).

What is Recursion Pharmaceuticals’s revenue growth rate?

Recursion Pharmaceuticals's revenue growth rate for the last 3 years (2022-2024) was 48.28%, and for the last 5 years (2020-2024) was 1623.97%.

What are Recursion Pharmaceuticals’s revenue streams?

Recursion Pharmaceuticals's revenue streams in c 24 are License and Service, and Grant. License and Service generated $58.49M in revenue, accounting 99.40% of the company's total revenue, up 33.30% year-over-year. Grant generated $351K in revenue, accounting 0.60% of the company's total revenue, down -49.79% year-over-year.

What is Recursion Pharmaceuticals’s main source of revenue?

For the fiscal year ending Dec 24, the largest source of revenue of Recursion Pharmaceuticals was License and Service. This segment made a revenue of $58.49M, representing 99.40% of the company's total revenue.